Epidemiological and treatment-related factors contribute to improved 1 outcome of oropharyngeal squamous cell carcinoma in Finland 2 3 Background: Treatment for oropharyngeal squamous cell carcinoma (OPSCC) has 4 changed, as the proportion of HPV-related disease has increased. We evaluated 5 nationwide information on its management and outcome during the treatment paradigm 6 change period.
Introduction 31
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased 32 during the last decades [1-4]. More precisely, the incidence rates for palatine tonsil (PT) 33 and base of tongue (BOT) squamous cell carcinoma (SCC) have increased [1] , and 1 oncogenic human papilloma virus (HPV) infection is likely responsible for this trend 2
[5]. Due to differences in cancer biology, the HPV-associated form of OPSCC is 3 considered to be a distinct disease entity, whereas the HPV-negative OPSCC, with a 4 declining incidence, is biologically more closely associated to other non-HPV-5 associated HNSCCs [6] . In the carcinogenesis of HPV-associated OPSCC, the tumor 6 suppressor protein, retinoblastoma, is inactivated. This leads to tumor suppressor 7 protein p16 overexpression [7] , which is used as an indirect surrogate marker for HPV 8 association in OPSCC [8] . HPV-positive OPSCC, which has survival rates even 50% 9 higher than its virus-negative counterparts [9] , tends to present at a low T class, but with 10 a more advanced N class resulting in a more advanced stage at diagnosis [10] [11] [12] . 11
There is a lack of consensus regarding the optimal management of OPSCC, as 12 the outcome results after both definitive oncological treatment and combined treatment 13 have been shown to be relatively similar [10, 13-16] The extent of treatment is typically 14 adjusted according to factors such as disease stage, patients' general condition, and 15 comorbidity [17, 18] . Modifications of the treatment protocol, according to HPV status, 16
should still be experimental [17] [18] [19] , although the 8 th Edition of UICC TNM 17 classification characterizes OPSCC into two distinct subgroups depending on the HPV 18 association of the tumor [20] . 19
Treatment planning warrants new perspectives, as HPV-positive OPSCC is 20 suggested to have better survival regardless of treatment modality [10, 11] . According 21 to studies by Ang et al. [5, 10] , HPV status (or p16 status), smoking history, and T and 22 N classes can be used to stratify OPSCC patients into three groups with characteristic 23 overall survival rates. In addition, comorbidity may also be used to stratify OPSCC 24 patients into three groups having distinct survival rates [21] . Several randomized studies 25 evaluating the OPSCC treatment, especially in smaller tumors, are ongoing [22] . 1
In the history, both primary oncological approach and primary surgical approach 2 have been considered as optimal treatment modalities for OPSCC, and the protocol 3 shifts have been attributed to the advances in technology [23] . For some decades, at 4 many centers, surgery used to have a more significant role in the treatment of OPSCC. 5
Later on, delivery of definitive chemoradiotherapy has been increasing, reflecting an 6 aim at better functional outcome as majority of patients remain without surgical 7
intervention. [24, 25] However, surgery in treatment of a selected OPSCC patient group 8 may also be beneficial and the rate of surgeries may be currently increasing [23] . 9
Head and neck cancer management is centralized to the five university hospitals 10 in Finland, with a population of 5.5 million people. The Finnish Head and Neck 11
Oncology Working Group maintains national treatment guidelines for these 12 malignancies. The objective of this nationwide Finnish multicenter study is to describe 13 the given treatments and patient outcome in an unselected series of OPSCC tonsillar fossa, and tonsillar pillars), anterior wall (base of tongue and vallecula), 5 superior wall (soft palate and uvula), and posterior wall. We also included patients with 6 subsequent follow up, or postoperative RT or CRT given at other hospitals. In these 7 cases, postoperative oncological treatment was carried out according to the same 8 national guidelines. The dates and causes of death were provided by Statistics Finland. 9
A combination treatment (Sx + RT or CRT) was classified as complete if surgery was 10 followed by postoperative RT of at least 45 Gy, and definitive RT or CRT were 11 classified as complete if patients had at least 60 Gy of RT. CT was recorded if at least 12 one cycle was implemented. Of all patients who received treatment with curative intent 13 99% and 75% had a minimum of 3-year and 5-year follow-up or until death. This study 14 was approved by the institutional Research Ethics Board (record number: 15 179/13/03/02/2013) and a study permission was granted. 16 17
Immunohistochemistry 18
Formalin fixed paraffin blocks were collected from the pathology archives of each 19 hospital. Among the patients with curative intent of treatment, 431 (71.8%) had their 20 tumor block available for p16 immunohistochemistry. The tumor was regarded as p16 21 positive if more than 70% of tumor cells were strongly immunopositive. 22
23

Statistical analysis 24
SPSS Version 20.0 (SPSS, Inc., Chicago, IL, USA) was used in the statistical analyses. 1
The chi-square test with asymptotic or exact P-value explored the statistical associations 2 of categorical variables. Independent samples T-test was used for continuous variables, 3 and normal distribution was observed from histogram. For survival analysis, we used 4 the 3-and 5-year overall survival (OS), disease-specific survival (DSS), disease-free 5 survival (DFS), and recurrence-free survival (RFS) in the Kaplan-Meier (KM) estimate. 6
The statistical test of survival analysis was the Log rank test. The maximum length of 7 follow-up was adjusted to five years to minimize the possibility of follow-up bias. 
Results
20
Patient population 21
A total of 674 patients with an invasive OPSCC or its histologic variant were identified 22 ( Figure 1 ). There were 500 (74.2%) males and 174 (25.8%) females, with the mean age 
Incomplete treatment with curative intent 9
The treatment was classified incomplete in 36 (6.0%) patients. Of these, 23 patients had 10 advanced OPSCC, Stage III-IV, but no oncological postoperative treatment was offered 11 because of patient-related reasons such as severe comorbidities or patients refusal, or 12 previous RT for a former head and neck malignancy. Postoperative RT was initiated, 13
but not completed in one patient. Definitive RT was not carried out entirely up to the 14 prescribed dose in 12 patients. 15
16
Palliative treatment 17
Of all patients, 74 (11.0%) primarily received palliative treatment. The disease stages 18 were as follows: Stage II n=1; III n=2; IVA n= 30; IVB n=17; IVC n=18. The exact 19 staging was not available for six patients. Palliative RT was delivered to 26 patients, 20 palliative CT to four patients, palliative CRT to three patients, and boron neutron 21 Altogether 120 patients (20%) developed a recurrent disease within five years, 9
and 84% of these occurred within three years. The recurrence was detected first at 10 locoregional site in 76 patients, first at distant site in 38 patients, and concurrently at 11 locoregional and distant sites in 6 patients. A locoregional recurrence developed more 12 often in patients with a p16-negative tumor. A distant recurrence developed nearly as 13 often in patients with a p16-positive and p16-negative tumor ( Supplementary Table 1 ). 14
15
Outcome 16
Treatment outcome after curative treatment intent 17
The 3-and 5-year OS, DSS, and DFS rates are shown in Table 2 . DSS stratified by T 18 class, N class, stage, p16, and treatment are presented in Figure 2 . Patients carrying a 19 p16-positive tumor had a better 5-year DSS (81.0%) than those with a p16-negative 20 tumor (57.2%). In addition, the group who underwent primary surgery as part of their 21 treatment had a better 5-year DSS (76.3%) compared with to the group receiving 22 definitive oncological treatment (66.7%). We also analyzed the p16-positive and p16- Multivariate analysis is presented separately for patients with lateral and anterior wall 18 OPSCC, because a statistically significant interaction occurred between primary tumor 19 localization and treatment (definitive CRT  Salvage Sx vs. Sx + (C)RT) (P = 0.013), 20 primary tumor localization and RT modality (3D conformal RT vs. IMRT) (P = 0.001), 21 and primary tumor localization and N class (P = 0.037). Due to low incidence of 22 superior and posterior wall OPSCC, patients having tumors at these sites were not 23 included in multivariate analysis. In lateral wall OPSCC, p16 negativity, presence of 24 regional metastasis, and male sex were associated with increased 5-year disease 25 mortality. In anterior wall OPSCC, p16 negativity, 3D conformal RT (in comparison to 1 IMRT), classes T3-T4, and male sex were associated with increased 5-year disease 2 mortality. 3 4 5 6 Discussion 7
We conducted a ten-year survey of all OPSCC patients treated at the five university 8 hospitals to evaluate the treatment outcome in a nationwide series of 674 patients. 9
During the study period the annual number of OPSCC patients increased, as a result of 10 increase in the p16-positive cases. 11
This study is a continuum to the earlier nationwide retrospective cohort study 12 including all patients diagnosed and treated at the five Finnish university hospitals 13 between 1995 -1999 [27]. In the earlier series, the 5-year DSS of patients with lateral 14 wall tumors was 73%, compared to present our 75%. The 5-year DSS of patients with 15 an anterior wall OPSCC had improved slightly from 47% to 65% (Table 2 ). In the 16 1990s, surgery followed by radiotherapy was the mainstay of treatments for OPSCC 17 patients in Finland, as up to 85% of all patients had surgery for their primary tumors 18
[27]. Consistent with other reports [24, 25] , during the last years of this study, definitive 19 oncological treatment became a standard ( Supplementary Figure 1) . Surgery still has a 20 significant role for many of these patients, and the actual rate of surgeries did not 21 decrease during the study period. In our material, 49% of patients treated with a curative 22 intent, underwent primary surgery, which despite the changing trends in the 23 management has been suggested to have an important role e.g. in HPV or p16-negative wall OPSCC decreased during the study period, as the use of CRT for the same site 24 increased (data not shown). During our study period, robotic surgery was not available 25 and more research is needed to sort out its role, especially in the treatment of small 1 primary tumors. Statistically significant interactions between treatment related factors 2 remained absent. 3
In our material, positive surgical margins on histology did not have a statistically 4 significant effect on survival ( Supplementary Figure 2) . All pertinent surgical 5 procedures in the present series were carried out with the aim at achieving clear 6 microscopic margins. Nevertheless, positive surgical margins still occurred in one fifth 7 of the cases. Some earlier reports have also suggested that even non-radical surgery may 8 improve survival in tonsillar SCC [33, 34] . We may therefore speculate that oncological 9 treatment may be more efficacious on microscopic residual tumor cells when the 10 primary tumor has been macroscopically resected. 11
Our results showed that as compared with conventional RT, IMRT was 12 significantly associated with improved outcome among patients with p16-negative was seen among patients with a large primary tumor (T4 class), but although number of 5 patients with a T4b tumor was small, these patients had clearly worse outcome than 6 those with a T4a tumor. The outcome of patients with p16-positive N0-N2b disease was 7 relatively good, and the outcome was impaired only among patients with N2c or N3 8 disease, which matches well with the current 8 th Edition of UICC TNM classification. 9
However, the number of patients with N3 tumor was also too small to draw any firm 10 conclusions. Among patients with p16-negative OPSCC only those with stage I disease 11 had a relatively good survival rate, and the outcome gradually worsened with more 12 advanced T and N classes. Interestingly, those patients who had stage II p16-negative 13 OPSCC clearly had a poor outcome suggesting that they may have been either 14 Despite national treatment guidelines, the treatment is always individually 20 tailored causing some variations between given treatments. All patients are not suitable 21 for obtaining CRT, and in such cases surgery with postoperative RT may be a more 22 appropriate treatment option. Notably, in about one third of the patients receiving 23 definite CRT it was not possible to administrate all cycles of CT. RT is not considered 24 an optimal treatment for large necrotic lymph nodes, even though RT or CRT might 25 otherwise be the recommended treatment option [40] . The theoretical basis for this is 1 that tumors containing large amounts of hypoxic cells are more resistant to radiotherapy 2
[41]. For those patients presenting with a large necrotic lymph node metastasis -and 3 typically with a small p16-positive primary tumor -surgery, possibly neck dissection 4 (ND) alone, followed by CRT or RT is often carried out at our institutions. 5
This study presents a large unselected, nationwide and consecutive series of all 6 OPSCC patients treated in Finland. Due to the national health care system, all patients 7 had equal access to treatment, and therefore the socioeconomic factors affecting the 8 treatment selection are limited. Furthermore, the five Finnish university hospitals have 9 similar treatment facilities and patient compliance to follow-up is generally good. Due 10 to the retrospective nature of this study, some clinical data, like information on smoking 11 history, remained partly limited. In addition, tumor tissue unavailability limited p16-12 status determination, as it was available in only 72% of the patients. Our data suffered 13 from these limitations and from lack of a comorbidity or performance index. Therefore, 14 comparison between treatment methods must be done with special caution as selection 15 bias may be present. p16 and smoking status had a significant correlation (Gamma 16
Value -0.808) with each other. In addition, smoking data was fairly limited, and 17 especially the number of non-smokers was limited in anterior-wall disease resulting in 18 extensive confidence intervals. Thus, we excluded smoking status from the multivariate 19 analysis. The p16 status did not have an effect on the chosen treatments since it was 20 very rarely available at the time of treatment decision. In addition, our study remained 21 as survival data evaluation, and lacked evaluation of functional outcome. 22
In conclusion, we demonstrated that from 2000 to 2009, the incidence of 23 OPSCC increased countrywide, which occurred along with the increase in the number 24 of patients with p16-positive tumors. These patients had a better survival rate than those 25 with p16-negative tumors, which is in accordance with previous studies. Along with the 1 increased incidence, treatment had changed towards to a more oncological approach. In 2 anterior-wall disease a decrease in the rate of surgical treatment with concurrent 3 improvement in the outcome was observed. This improved outcome was mainly 4 associated with p16 positivity but also with developments in oncological treatment. In 5 lateral-wall disease, the rate of surgical treatment remained higher throughout the study 6 period. The role of surgery in the management of OPSCC disease requires further 7 investigation. 8 9 Acknowledgements: We express our gratitude to colleagues at the Finnish Central Hospitals All models are adjusted with Age, Sex, T class, N class, p16, treatment (Sx + (C)RT = Surgery + (chemo)radiotherapy vs. CRT ± Sx = Chemoradiotherapy ± Salvage surgery), and radiotherapy modality (3D = 3D conformal radiotherapy vs IMRT = Internsity-modulated radiotherapy) HR = Hazard ratio, CI = Confidence interval
